We're not optimistic about the future commercialization of A166/SKB264. As a company without sustainable growth capability, traditional financial model doesn't work. We shared our views on valuation.
Boomeranged on Wed, 12 Jul 2023 09:25
Currently, Kelun-Biotech's market value has already been higher than that of Keymed. Considering Keymed has complete R&D team within the company, strong license-out deal with AZ, as well as NDA stage big variety CM310, we think its market value could be surpass Kelun-Biotech in the future. Thus, we recommend investors to be rational when trading Kelun-biotech.
SUMMARY
(Sign Up to Access)
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
Unlock all research summaries
Follow top, independent analysts
Receive personalised alerts and emails
Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.